What Researchers Did
A researcher reviewed published literature on using HBOT as an add-on treatment for glioma (primary brain tumors) and brain metastases, focusing on its combination with radiation therapy.
What They Found
HBOT can reduce tumor hypoxia and increase radiosensitivity, potentially improving survival when combined with radiotherapy for glioma. For brain metastases, combining HBOT with stereotactic radiosurgery appears both safe and beneficial, offering protection against radiation-induced brain injury and supporting neurological and motor function recovery. Adverse reaction rates for HBOT were described as relatively low.
What This Means for Canadian Patients
Brain tumor patients in Canada undergoing radiation treatment may benefit from adding HBOT to their care plan, particularly to protect healthy brain tissue from radiation damage and to improve how well tumors respond to treatment. This could be especially relevant for patients with brain metastases receiving focused radiation.
Canadian Relevance
Radiation-induced brain injury may qualify as delayed radiation injury, which is an OHIP-covered indication for HBOT in Ontario.
Study Limitations
This is a narrative literature review without formal systematic search methodology or risk-of-bias assessment, so evidence quality cannot be formally rated.